コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 National Institute for Health Research Health Technology Assessment.
2 hed articles and Thai Standard Cost List for Health Technology Assessment.
3 orting of modeling and simulation studies in health technology assessment.
4 rences that complicate research questions in health technology assessment.
5 ational Institute for Health Research (NIHR) Health Technology Assessment.
6 nstitute for Health and Care Research (NIHR) Health Technology Assessment.
7 NIHR) School for Primary Care Research, NIHR Health Technology Assessment.
8 ional Institute for Health and Care Research Health Technology Assessment.
11 arch was complemented by a consultation with health technology assessment agencies belonging to the m
12 for treatment of metastatic breast cancer by health technology assessment agencies suggested that per
13 ntified from PubMed, Embase, Cochrane, MEDES health technology assessment agencies, and scientific co
14 ional Institute for Health and Care Research Health Technology Assessment and Motor Neurone Disease A
15 derstanding of novel multimorbid phenotypes, health technology assessment and patient-centred shared
16 c reviews, clinical practice guidelines, and health technology assessments and addresses issues of in
17 information and publicly available data from health technology assessments and logistic and linear re
18 cost-effectiveness and decision analysis in health technology assessment, and describe unique featur
19 ces, adopting methodological developments in health technology assessment, and prospective registrati
20 of care between referral centers, to perform health technology assessment, and to guide decision-maki
21 atory and transfusion medicine, haematology, health technology assessments, and population screening-
22 n an RCT may be important for regulatory and health technology assessment approvals; (7) in the absen
23 nalyses, two retrospective analyses, and two health technology assessments based on a systematic revi
24 studies; (2) engagement with regulators and health technology assessment bodies about RCT design is
27 cies, academia, the pharmaceutical industry, health-technology assessment bodies, and patient advocat
28 Foundation, Danish Centre for Evaluation and Health Technology Assessment, Danish National Board of H
29 l Practice, Danish Centre for Evaluation and Health Technology Assessment, Danish National Board of H
30 e of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database (HTA), MEDLINE, EM
31 of Abstracts of Reviews of Effects, and the Health Technology Assessment database through February 2
32 e Central Register of Controlled Trials, and Health Technology Assessment Database was conducted from
33 hrane Central Register of Controlled Trials, Health Technology Assessment Database, MEDLINE, and Emba
34 Database of Abstracts of Reviews of Effects, Health Technology Assessment Database, National Institut
35 e Central Register of Controlled Trials, and Health Technology Assessment Database, were obtained, in
37 Database of Abstracts of Reviews of Effects; Health Technology Assessment Database; Health Systems Ev
38 DLINE, EMBASE, CINAHL, LILACS, Cochrane, and Health Technology Assessments databases were searched fo
39 ive officers in surgical device procurement, health technology assessment experts, and hospital direc
40 t utility or cost effectiveness analysis for health technology assessment, health policy, and reimbur
41 relates to the fundamental questions for all health technology assessment, "How much does this interv
46 ational Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme, and NIHR C
47 ational Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme, and the De
48 and analyze English, French, and Australian health technology assessments (HTAs) of all new cancer m
49 lications for regulatory decision-making and health technology assessment in target populations outsi
51 ational Health and Medical Research Council, Health Technologies Assessment-National Institute for He
52 Health and Medical Research Council (NHMRC), Health Technologies Assessment-National Institute for He
56 National Institute of Health Research (NIHR) Health Technology Assessment, NIHR Respiratory Biomedica
57 s), notified bodies (for devices in Europe), health technology assessment organisations, and payers s
58 ents, a survey of Web sites of international health technology assessment organizations, and input fr
61 nce (no date limits), and the United Kingdom Health Technology Assessment Program (January 1998 to De
64 ional Institute for Health and Care Research Health Technology Assessment Programme (grant reference
65 UK National Institute of Health Research Health Technology Assessment Programme (NIHR HTA), proje
73 ties, National Institute for Health Research Health Technology Assessment programme, Ninewells Cancer
74 ties, National Institute for Health Research Health Technology Assessment programme, Ninewells Cancer
76 , The National Institute for Health Research Health Technology Assessment Programme, The MRC Clinical
77 ional Institute for Health and Care Research Health Technology Assessment Programme, UK Multiple Scle
78 Trust, UK Medical Research Council, UK NIHR Health Technology Assessment Programme, UK National Heal
100 ited States, several European countries have health technology assessment programs for drugs, many of
101 ute, foreign government agencies involved in health technology assessment, public and private payers,
102 ory review, time from regulatory approval to health technology assessment recommendation (England, Sc
103 cal benefit, time to regulatory approval and health technology assessment recommendations, reimbursem
104 akeholders (academic, independent, industry, health technology assessment, regulatory, and patient ad
105 oved extremely useful in systematic reviews, health technology assessment reports, and clinical pract
107 lel-group, double-blind, placebo-controlled, Health Technology Assessment Study of the Use of Antidep
108 eference pricing, therapeutic valuation, and health technology assessment to determine the appropriat
109 mple is priority setting using tools such as health technology assessment to guide the optimum diffus
110 he same time, and access, after a successful health technology assessment, was considerably delayed o